 |
|
|
| |
|
|
L. Patrick Gage, Ph.D.
Chairman
Dr. Gage has served as Chairman of the Board of Directors since December 2011. Dr. Gage has nearly 40 years of experience in the life science industry. Since July 2002, Dr. Gage has served as a consultant to the biopharmaceutical industry, including service as an advisor to venture capital firms. From 1998 to 2002, Dr. Gage was President of Wyeth Research and subsequently also Senior Vice President, Science and Technology. From 1989 to 1998, he held roles of increasing responsibility at Genetics Institute, Inc., first as head of Research and Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989, Dr. Gage held various positions in research management with Hoffmann-La Roche Inc., most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage served on the Board of Directors of Neose Technologies from 2002 through 2009, and as the Chairman of its Board of Directors from 2006 through 2009. He served on PDL BioPharma, Inc.’s Board of Directors from 2003 through 2008, as the Chairman of its Board of Directors in 2007, and as its Interim Chief Executive Officer from 2007 through 2008. Dr. Gage served on the Board of Directors of Serono (now a subsidiary of Merck KGaA) from 2004 until 2007. He also has served on the board of Cytokinetics since November 2009 and as Chairman of the Board of Directors since March 2010. Dr. Gage earned a bachelor's degree in Physics from the Massachusetts Institute of Technology and a Ph.D. in Biophysics from the University of Chicago.
|
 |
|
|
|
Garen Bohlin
Independent Director
Garen Bohlin is currently Executive Vice President of Constellation Pharmaceuticals serving in a senior advisory capacity. Before Constellation, he held senior executive posts over a 25-year period in leading biotechnology companies. Immediately prior to Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, where he held key general management positions, and played a key role in the company’s initial public offering, the sale of the company to GlaxoSmithKline for over $700 million, and the post-acquisition integration. Previously, he was the founding CEO of Syntonix Pharmaceuticals where he positioned the company for its eventual sale to Biogen Idec. Earlier in his career, he held multiple executive positions at Genetics Institute, where he managed over 800 people and played an integral role in structuring its sale to American Home Products (Wyeth) at an implied valuation of approximately $3 billion. Prior to his biotechnology industry roles, Mr. Bohlin was a partner in Arthur Andersen's world headquarters in Chicago.
Mr. Bohlin currently serves on the Board of Acusphere, Inc., SpringLeaf Therapeutics, Inc., and was also a Board member and past chair of the Massachusetts Biotechnology Council.
|
|
|
|
|
Douglas Cole, M.D.
Flagship Ventures
Douglas Cole is a partner at Flagship Ventures, where he focuses on life science investments. He currently serves on the Boards of Directors of Ensemble Therapeutics, Tetraphase, Concert Pharmaceuticals, Quanterix, Receptos, Agios, Selecta Biosciences, Avedro, Resolvyx Pharmaceuticals and AVEO Pharmaceuticals, and is an Observer on the Board of Directors of Alvine. He formerly served on the Boards of Directors of CombinatoRx and Morphotek.
Dr. Cole is a member of the Scientific Advisory Board of the Spinal Muscular Atrophy Foundation, the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics, the Scientific Advisory Board of the Massachusetts Life Sciences Center, and serves on the Board of Directors of the Birch Rock Camp in Waterford, ME.
Prior to Flagship, Dr. Cole held senior management positions at Vertex Pharmaceuticals and Cytotherapeutics. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA.
|
|
|
|
|
Eric M. Gordon, Ph.D.
Skyline Ventures
Dr. Gordon is a partner at Skyline Ventures and has been a distinguished medicinal chemist, company founder and senior executive since the early 1970s. He was head of medicinal chemistry at Squibb and Bristol Myers Squibb in Princeton, where he worked for 18 years. In 1992, he was Vice President of Research and Director of Chemistry at Affymax in Palo Alto, and in 1996, he became scientific co-founder, President and Chief Scientific Officer of Versicor (later Vicuron Pharmaceuticals, which was acquired by Pfizer in 2005). He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition.
He received his Ph.D. and M.S. in medicinal chemistry from the University of Wisconsin in Madison and conducted post-doctoral work at Yale University.
|
|
|
|
Steve Gullans, Ph.D.
Excel Venture Management
Dr. Gullans is a co-founder and partner at Excel Venture Management. At Excel he focuses on life science technology companies with particular interest in broadly applicable disruptive platforms. He is currently a Director at Biocius Biosciences and RxGen and was a board member of BioTrove until it was acquired by Life Technologies (LIFE). He also advises Aileron and US Genomics and formerly advised GeneOhm (acquired by Becton Dickinson - BDX) and other biotech companies.
Prior to co-founding Excel, Dr. Gullans co-founded RxGen, Inc., a pharma services company where he served as CEO from 2004-2008. In 2002, Dr. Gullans stepped in as a senior executive at US Genomics for two years to direct operations, recruit a new CEO, and assist with fundraising.
Dr. Gullans is an expert in advanced life science technologies and was a faculty member at Harvard Medical School and Brigham and Women's Hospital for nearly 20 years. He has published more than 120 scientific papers in many leading journals, lectured internationally, and co-authored many patents. He received his B.S. at Union College, Ph.D. at Duke University, and postdoctoral training at the Yale School of Medicine.
|
|
|
|
Karl D. Handelsman
CMEA Ventures
Mr. Handelsman joined CMEA Ventures in February 1999. He has been involved with numerous CMEA investments such as: Ambrx, Ensemble Discovery, Ilypsa, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, and Xenoport. Prior to joining CMEA, Mr. Handelsman was one of the first employees of Tularik, Inc., a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. He was also one of the first employees of the Whitehead Institute, a premier research organization within MIT; and he worked in business development at Millennium Pharmaceuticals (now a Takeda company).
Mr. Handelsman holds graduate degrees from both MIT and Harvard Medical School.
|
|
|
|
|
Guy Macdonald, B.Sc.
Tetraphase
Mr. Macdonald has served as Tetraphase’s President and CEO since January 2008. He has enjoyed a successful 25-year career in global pharmaceutical and biotechnology. Prior to joining Tetraphase, he was Executive Vice President, Operations, Idenix Pharmaceuticals where he played the lead role in developing the commercial organization in the U.S. and top five EU countries and was responsible for Regulatory Affairs, Quality Assurance, Manufacturing, Information Technology and Project Management.
Mr. Macdonald previously spent 22 years at Merck & Co., Inc., initially in the UK, followed by senior positions in the U.S., culminating as the Vice President for Anti-infective and Hospital Products with sales of more than $1.4 billion. At Merck, Mr. Macdonald had a distinguished career as a senior leader in the areas of virology and anti-infectives, which included a number of landmark product launches at a global level.
Mr. Macdonald received an Honours Degree in Biochemistry from Dundee University, Dundee, Scotland.
|
|
|
|
|
Lawrence Miller, M.D.
Mediphase Venture Partners
Dr. Miller is a Partner and Founder of Mediphase Venture Partners and Mediphase Capital Partners. He has invested in more than 25 private companies in life sciences/health care.
Prior to founding Mediphase Venture Partners, Dr. Miller was Senior Vice President, Hambrecht & Quist Capital Management in Boston from 1997-1999, where he was responsible for evaluating all healthcare private equity investments.
Dr. Miller is trained as a physician and pharmacologist and is currently Adjunct Associate Professor of Pharmacology at Tufts and Instructor in Medicine at Harvard Medical School.
|
|
|
|
|
Robert Weisskoff, Ph.D.
Fidelity Biosciences
Dr. Weisskoff has worked extensively in both academia and the bioscience industry for the past 18 years. Prior to joining Fidelity in 2004, he held various senior roles in R&D and Business Development at pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. |
|
|
|
|
|
|
|
|
